Siyu Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Siyu Zhao has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Chao Tang
Department of Orthopedics, Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou, Henan, People’s Republic of China
1 shared publication Cheng Cheng
Department of Orthopedics, Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou, Henan, People’s Republic of China
1 shared publicationHaodong Peng
Department of Thoracic Surgery, Henan Provincial People’s Hospital, Zhengzhou, People’s Republic of China
1 shared publicationJia Zheng
Department of Orthopedics, Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou, Henan, People’s Republic of China
1 shared publication- Jianjun Wang
Department of Thoracic Surgery, Henan Provincial People’s Hospital, Zhengzhou, People’s Republic of China
1 shared publication Junfeng Yang
Department of Thoracic Surgery, Henan Provincial People’s Hospital, Zhengzhou, People’s Republic of China
1 shared publication
Latest Publications
- Open Access
- 1 September 2026
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 19, 1-20
ITGBL1 and RPN1 Mark a Fibrotic NP Subpopulation with Coupled Integrin Signaling and N-Glycosylation Programs in IVDD
Background: FibroNPC is a degeneration associated subtype in intervertebral disc degeneration (IVDD), yet its markers and immune crosstalk remain poorly characterized. ITGBL1 and RPN1 recur as IVDD associated genes in bulk studies, but where they are expressed within the heterogeneous disc has not been resolved. Methods: Three GEO datasets comprising 81 bulk profiles were integrated and screened by LASSO, SVM-RFE, and Random Forest, with external validation in an independent 15 sample cohort. Two human IVDD scRNA-seq cohorts were analyzed by subclustering, signature scoring, and within scRNA-seq per-subpopulation contribution analysis. CellChat, AUCell pathway scoring, and drug prediction were used as exploratory analyses; IL-1β stimulated HNPCs served as the in vitro model. Results: Machine learning analysis prioritized ITGBL1 and RPN1 as consensus core genes (combined AUC = 0.925), with their differential expression further supported in an independent external cohort. Single cell mapping preferentially localized both genes to a FibroNPC subpopulation and associated this cell state with coupled integrin/focal adhesion and ER protein processing/N-glycosylation programs. Notably, although FibroNPCs comprised less than one-fifth of NP/AF cells, they contributed approximately 48% of total ITGBL1 expression and disproportionate shares of several canonical fibrotic transcripts. CellChat further inferred increased macrophage SPP1–integrin communication involving structural cell populations in IVDD. In IL-1β stimulated HNPCs, both ITGBL1 and RPN1 were increased at the mRNA and protein levels. Conclusion: ITGBL1 and RPN1 represent FibroNPC associated molecular markers linked to coupled integrin signaling and N-glycosylation programs in IVDD. The disproportionate contribution of FibroNPCs to ITGBL1 and fibrotic gene expression highlights the importance of cell state resolved localization beyond conventional bulk hub-gene identification. Further functional validation is required before therapeutic implications can be established.
- 1 September 2026
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 19, 1-20
Open AccessITGBL1 and RPN1 Mark a Fibrotic NP Subpopulation with Coupled Integrin Signaling and N-Glycosylation Programs in IVDD
Background: FibroNPC is a degeneration associated subtype in intervertebral disc degeneration (IVDD), yet its markers and immune crosstalk remain poorly characterized. ITGBL1 and RPN1 recur as IVDD associated genes in bulk studies, but where they are expressed within the heterogeneous disc has not been resolved. Methods: Three GEO datasets comprising 81 bulk profiles were integrated and screened by LASSO, SVM-RFE, and Random Forest, with external validation in an independent 15 sample cohort. Two human IVDD scRNA-seq cohorts were analyzed by subclustering, signature scoring, and within scRNA-seq per-subpopulation contribution analysis. CellChat, AUCell pathway scoring, and drug prediction were used as exploratory analyses; IL-1β stimulated HNPCs served as the in vitro model. Results: Machine learning analysis prioritized ITGBL1 and RPN1 as consensus core genes (combined AUC = 0.925), with their differential expression further supported in an independent external cohort. Single cell mapping preferentially localized both genes to a FibroNPC subpopulation and associated this cell state with coupled integrin/focal adhesion and ER protein processing/N-glycosylation programs. Notably, although FibroNPCs comprised less than one-fifth of NP/AF cells, they contributed approximately 48% of total ITGBL1 expression and disproportionate shares of several canonical fibrotic transcripts. CellChat further inferred increased macrophage SPP1–integrin communication involving structural cell populations in IVDD. In IL-1β stimulated HNPCs, both ITGBL1 and RPN1 were increased at the mRNA and protein levels. Conclusion: ITGBL1 and RPN1 represent FibroNPC associated molecular markers linked to coupled integrin signaling and N-glycosylation programs in IVDD. The disproportionate contribution of FibroNPCs to ITGBL1 and fibrotic gene expression highlights the importance of cell state resolved localization beyond conventional bulk hub-gene identification. Further functional validation is required before therapeutic implications can be established.
- Open Access
- 1 May 2026
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 19, 1-12
Genetic Evidence for Immune Cell-Lipid Mediation Pathways Linked to Esophageal Cancer and Associated Throat/Chest Pain Phenotypes
Purpose: Previous studies showed complex associations between immune cells and esophageal cancer (EC). EC-related pain is closely linked to immune dysregulation and abnormal lipid metabolism, but their synergistic regulatory mechanisms remain unclear. This study aimed to investigate causal relationships between immune cell traits and EC, explore plasma lipids’ mediating role, supplement genetic evidence for core immune factors-lipids-pain associations, and provide targets for EC’s combined “ Antineoplastic-analgesic” intervention. Methods: Genome-wide association study summary data of 731 immune cell traits, 179 lipid metabolites, 998 EC cases, and two pain-related datasets were compiled. Bidirectional MR analysis (with inverse variance weighting, MR-Egger, MR-RAPS, weighted median, weighted mode) was used to infer causal relationships, followed by sensitivity analyses for robustness and FDR correction (Benjamini-Hochberg method) to account for multiple testing. A two-step Mendelian randomization was applied to explore plasma lipids mediating role in the immune cell-EC risk link. Results: This study identified 24 immune cell phenotypes and 14 plasma lipids suggestive causal associations with EC risk. Mediation analysis revealed that HLA DR on CD33dim HLA DR+ CD11b+ affected EC risk via Phosphatidylcholine (18:0_22:6) levels, with a suppression ratio of − 82.15%, indicating an exploratory indirect effect that partially offsets the primary protection. Similarly, Phosphatidylcholine (O-18:1_20:4) exhibited a suggestive suppression effect (− 10.38%) on the association between SSC-A on CD8+ T cell and EC risk. Furthermore, CD3 on HLA DR+ T cells showed a negative association with both pain-related datasets. CD33 on basophils and SSC-A on CD8+ T cells showed a positive association. Sensitivity analyses showed no significant abnormalities. Conclusion: This study systematically identified immune cell phenotypes causally associated with EC and highlighted key lipid mediators underlying these effects. The core immune cell phenotypes and lipids are not only associated with EC risk but also show consistent genetic associations with typical EC-related pain symptoms, suggesting the existence of a co-regulatory network. These findings provide new insights into the mechanism and combined intervention of EC-related pain.
- 1 May 2026
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 19, 1-12
Open AccessGenetic Evidence for Immune Cell-Lipid Mediation Pathways Linked to Esophageal Cancer and Associated Throat/Chest Pain Phenotypes
Purpose: Previous studies showed complex associations between immune cells and esophageal cancer (EC). EC-related pain is closely linked to immune dysregulation and abnormal lipid metabolism, but their synergistic regulatory mechanisms remain unclear. This study aimed to investigate causal relationships between immune cell traits and EC, explore plasma lipids’ mediating role, supplement genetic evidence for core immune factors-lipids-pain associations, and provide targets for EC’s combined “ Antineoplastic-analgesic” intervention. Methods: Genome-wide association study summary data of 731 immune cell traits, 179 lipid metabolites, 998 EC cases, and two pain-related datasets were compiled. Bidirectional MR analysis (with inverse variance weighting, MR-Egger, MR-RAPS, weighted median, weighted mode) was used to infer causal relationships, followed by sensitivity analyses for robustness and FDR correction (Benjamini-Hochberg method) to account for multiple testing. A two-step Mendelian randomization was applied to explore plasma lipids mediating role in the immune cell-EC risk link. Results: This study identified 24 immune cell phenotypes and 14 plasma lipids suggestive causal associations with EC risk. Mediation analysis revealed that HLA DR on CD33dim HLA DR+ CD11b+ affected EC risk via Phosphatidylcholine (18:0_22:6) levels, with a suppression ratio of − 82.15%, indicating an exploratory indirect effect that partially offsets the primary protection. Similarly, Phosphatidylcholine (O-18:1_20:4) exhibited a suggestive suppression effect (− 10.38%) on the association between SSC-A on CD8+ T cell and EC risk. Furthermore, CD3 on HLA DR+ T cells showed a negative association with both pain-related datasets. CD33 on basophils and SSC-A on CD8+ T cells showed a positive association. Sensitivity analyses showed no significant abnormalities. Conclusion: This study systematically identified immune cell phenotypes causally associated with EC and highlighted key lipid mediators underlying these effects. The core immune cell phenotypes and lipids are not only associated with EC risk but also show consistent genetic associations with typical EC-related pain symptoms, suggesting the existence of a co-regulatory network. These findings provide new insights into the mechanism and combined intervention of EC-related pain.